[ad_1]
Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ:RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (“Class Period”) have until this upcoming Tuesday, February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc.No. 21-cv-09585 (ND Cal.). Commenced on December 10, 2021, the Revance Therapeutics class action lawsuit charges Revance Therapeutics along with certain of its top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Revance Therapeutics class action lawsuit, please provide your information by clicking here. You can also contact attorney JC Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Revance Therapeutics class action lawsuit must be filed with the court no later than this upcoming Tuesday, February 8, 2022.
CASE ALLEGATIONS: Revance Therapeutics is a biotechnology company engaged in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. Revance Therapeutics’ lead drug candidate is DaxibotulinumtoxinA for injection (“DAXI”). In November 2019 , Revance Therapeutics issued a press release announcing that it had submitted a Biologics License Application (“BLA”) to the United States Food and Drug Administration (“FDA”) for DAXI to treat glabellar (fown) lines …
Full story available on Benzinga.com
[ad_2]
Source link
